Objective To investigate the value of plasma NT-proBNP levels in predicting the effect of drug conversion for paroxysmal atrial fibrillation.
Method The 132 patients with non-valvular paroxysmalatrial fibrillation were treated by oral loading – dose of propafenon (450–600 ng/l) within 1 h after admission. The plasma NT-proBNP concentrations were measured before and after conversion therapy.
Result Atrial fibrillation was converted to sinus rhythm in 83 patients (62.87%) after oral loading-dose of propafenone. The plasma NT-proBNP levels before drug conversion in patients with successful conversion were lower than that in patients with non-successful conversion (419.53±43.83) ng/l vs (458.11. 76±66.09) ng/l, p<0.01; and it decreased significantly after successful drug conversion (189.61±37.38) ng/l vs (419.53±43.83) ng/l, p<0.01. There was no significant difference of plasma NT-proBNP concentration before and after propefenone treatment (458.11. 76±66.09) ng/l vs (444.76±67.28) ng/l (p>0.05) in patients not converted to sinus rhythm. Receiver Operating Characteristic Curve (ROC curve) analysis was used to determine the optimal cut-off (432.25 ng/l) of this assay for identifying individuals who converted to sinus rhythm from those did not.
Conclusion Atrial fibrillation is a significant factor influencing the secretion of BNP in patients with non-valvular heart disease and plasma NT-proBNP levels can be used as a biomarker to predict the effect of drug conversion for paroxysmal atrial fibrillation.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.